ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1762

Multi-omic Analysis Defines Heterogeneous and Cell Specific Type I Interferon Signalling in Juvenile-onset SLE Patients Associated with Biomarkers of Cardiovascular Risk

Junjie Peng, Thomas McDonnell, Elizabeth Jury, Coziana Ciurtin and George Robinson, University College London, London, United Kingdom

Meeting: ACR Convergence 2024

Keywords: Cardiovascular, Genomics and Proteomics, immunology, interferon, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 18, 2024

Title: Pediatric Rheumatology – Basic Science Poster

Session Type: Poster Session C

Session Time: 10:30AM-12:30PM

Background/Purpose: Juvenile-onset systemic lupus erythematosus (jSLE) is an autoimmune disease characterised by chronic inflammation, multi-organ damage, and/or death. Despite their young age, jSLE patients have a 100-300-fold increased cardiovascular disease (CVD) risk, potentially associated with type I interferons (IFNs). We used multi-omics to explore the heterogeneity, cell specificity, and CVD risk associated with type I IFN signatures in jSLE.

Methods: RNA sequencing was used to assess differentially expressed genes (DEGs) in peripheral blood mononuclear cells (PBMCs) between jSLE patients with inactive disease (n=29, mean age/disease duration=19/6.5 years) and healthy controls (HCs, n=8, mean age=18). Data was analysed by weighted gene co-expression network analysis (WGCNA), pathway enrichment, hierarchical clustering, and receiver operating characteristic (ROC) analysis. Tetherin (established IFN-regulated protein) expression was quantified by spectral flow cytometry on PBMCs over a 30-parameter immune landscape (UMAP/FlowSOM). Proteomics (Olink) and Metabolomics (Nightingale) assessed serum proteins (validated by ELISA) and metabolites associated with CVD. Clinical data was analysed by trajectory analysis (mean 4.9 years/17 encounters).

Results: Independent of disease activity, type I IFN signalling was the most upregulated network module in jSLE patients compared to HCs (280 DEGs, p< 0.0001) from unbiased WGCNA. Despite this, jSLE patients clustered heterogeneously into high (H-IFN, 66%, ROC: p< 0.0001/AUC=1.00 vs HCs) and low (L-IFN, 34%, ROC: p=0.53/AUC=0.59 vs HCs) type I IFN signature groups, validated by established type I IFN gene scores (p< 0.0001).

Transcriptomic type I IFN scores in jSLE patients correlated positively with serum LAMP3 protein levels (Olink, p=0.0018/r=0.67). Furthermore, LAMP3 levels differentiated between H-IFN and L-IFN jSLE patients with strong accuracy (ROC: p=0.0069/AUC=0.95); this finding was validated by ELISA (ROC: p=0.027/AUC=0.89), and outperformed the biomarker accuracy of PBMC tetherin expression, supporting a more translational biomarker of H-IFN.

Importantly, no difference in clinical serology or disease activity trajectory was observed between type I IFN groups (well-controlled patients). However, transcriptomic type I IFN scores correlated positively with proteomic (galectin-9/ICAM1/VCAM1) and metabolomic (glycoprotein acetyls/ApoB:ApoA1) biomarkers, all heavily associated with CVD risk mechanisms (p< 0.01).

Finally, unbiased PBMC clustering identified relatively higher sensitivity to type I IFN (quantified by tetherin expression) in jSLE-specific sub-populations of B cells, plasmacytoid dendritic cells, CD8+ T cells, and NK cells.

Conclusion: Multi-omics allows us to better understand type I IFNs in jSLE: 1) patients have heterogeneous type I IFN signatures associated with CVD risk, independent from disease activity; 2) LAMP3 is an accurate serum biomarker that could stratify H-IFN patients in a clinical setting for tailored anti-IFN treatment to improve disease/CVD outcomes; and 3) specific immune populations may respond more favourably to anti-IFN therapy, providing mechanistic insight into treatment.


Disclosures: J. Peng: None; T. McDonnell: None; E. Jury: None; C. Ciurtin: None; G. Robinson: None.

To cite this abstract in AMA style:

Peng J, McDonnell T, Jury E, Ciurtin C, Robinson G. Multi-omic Analysis Defines Heterogeneous and Cell Specific Type I Interferon Signalling in Juvenile-onset SLE Patients Associated with Biomarkers of Cardiovascular Risk [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/multi-omic-analysis-defines-heterogeneous-and-cell-specific-type-i-interferon-signalling-in-juvenile-onset-sle-patients-associated-with-biomarkers-of-cardiovascular-risk/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/multi-omic-analysis-defines-heterogeneous-and-cell-specific-type-i-interferon-signalling-in-juvenile-onset-sle-patients-associated-with-biomarkers-of-cardiovascular-risk/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology